Abstract
Aldehyde dehydrogenases (ALDHs) are highly expressed in the chemotherapy- and radiotherapy-resistant cell subpopulations of many different cancer types. Accordingly, the development of ALDH inhibitors may be the most direct approach to target these cell populations. However, inhibiting multiple ALDH family members can be toxic and isoform-specific inhibition is often ineffective. This review discusses the role of ALDH in cancer and therapy resistance, and then overviews the various available ALDH inhibitors with a focus on the clinical potential and limitations of these agents as cancer therapeutics. Finally, challenges and future research directions to effectively target ALDH in the management of cancer therapy resistance are discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 774-789 |
| Number of pages | 16 |
| Journal | Trends in Pharmacological Sciences |
| Volume | 40 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2019 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Toxicology
- Pharmacology
Fingerprint
Dive into the research topics of 'Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver